Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers
Prostate cancer (PCa) is second only to lung cancer as a cause of death. Clinical assessment of patients and treatment efficiency therefore depend on the disease being diagnosed as early as possible. However, due to issues regarding the use of prostate-specific antigen (PSA) for screening purposes,...
Saved in:
| Main Authors: | Wei Jin, Xiang Fei, Xia Wang, Yan Song, Fangjie Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/8730608 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01) -
Are localized prostate cancer biomarkers useful in the clinical practice?
by: Arie Carneiro, et al.
Published: (2018-09-01) -
The proteomics in prostate cancer biomarker discovery
by: V. E. Shevchenko, et al.
Published: (2015-06-01) -
Increased GPR35 expression is correlated with poor prognosis in prostate cancer
by: Tianyi Zhang, et al.
Published: (2025-06-01) -
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus
by: Shahana Sarwar, et al.
Published: (2017-01-01)